Fluconazole Injection

This product is a new type of triazole antifungal drug that can specifically and effectively inhibit the synthesis of fungal sterols, that is, the synthesis of ergosterol, the main component of fungal cells. It also inhibits fungal peroxidase, leading to fungal death. Intravenous injection of this product is effective for various animal fungal infections, such as Candida infections (including systemic candidiasis and infections caused by immunosuppression in animals), Cryptococcus neoformans infections (including intracranial infections), Microsporum infections, and Trichophyton, Epidermophyton, Pityrosporum and other infections.

Chemical composition: Fluconazole.

This product is mainly used for patients with more severe conditions in the following indications: 1. Candidiasis: used to treat oropharyngeal and esophageal Candida infections; disseminated Candidiasis, including Candida vulvovaginitis such as peritonitis, pneumonia, and urinary tract infections. It can also be used to prevent the occurrence of Candida infections in bone marrow transplant patients receiving cytotoxic drugs or radiotherapy. 2. Cryptococcal disease: used to treat new cryptococci other than meninges; when treating cryptococcal meningitis, this product can be used as a maintenance treatment after initial treatment with amphotericin B combined with flucytosine. 3. Coccidioidomycosis. 4. This product can also replace itraconazole for the treatment of blastomycosis and histoplasmosis.

Intravenous drip. Adults 2 Esophageal candidiasis: The first dose is 0.2g, then 0.1g once a day, for at least 3 weeks, and at least 2 weeks after the symptoms are relieved. Depending on the treatment response, the dose can also be increased to 0.4g once a day. 3 Oropharyngeal candidiasis: The first dose is 0.2g, then 0.1g once a day, for at least 2 weeks. 4 Candida vulvovaginitis: Single dose, 0.15g. 5 Cryptococcal meningitis: 0.4g once a day, until the condition improves significantly, then 0.2-0.4g once a day.

1. Common gastrointestinal reactions include nausea, vomiting, abdominal pain or diarrhea. 2. Allergic reactions: may manifest as rash, and occasionally severe exfoliative dermatitis (often accompanied by liver damage) and exudative erythema multiforme. 3. Hepatotoxicity: Mild transient elevation of serum aminotransferase may occur during treatment, and symptoms of hepatotoxicity may occasionally occur, especially in patients with serious underlying diseases (such as AIDS and cancer). 4. Headache and dizziness may be seen. 5. Some patients, especially those with serious underlying diseases (such as AIDS and cancer), may have abnormal renal function. 6. Changes in hematological examination indicators such as transient neutropenia and thrombocytopenia in peripheral blood may occasionally occur, especially in patients with serious underlying diseases

Patients with a history of allergy to this product or other azole drugs are contraindicated.

Precautions for children: There is a lack of sufficient research data on the effects of this product on children. Although a small number of pediatric patients aged 2 weeks to 14 years old have not experienced adverse reactions when treated with a daily dose of 3-6 mg/kg (by body weight), it is still not suitable for children. Precautions for pregnancy and lactation: 1. In animal experiments, when this product is given to animals at high doses, miscarriage, increased stillbirths, rib deformities in young animals, cleft palate and other changes may occur. Although such conditions have not been found in humans, pregnant women should still not use it. 2. There is no data on the concentration of this product in breast milk, so lactating women should use it with caution or stop breastfeeding when taking this product. Precautions for the elderly: Elderly patients with no renal function impairment do not need to adjust the dose. Elderly patients with renal impairment should adjust the dose according to creatinine clearance (see [Usage and Dosage] for details).

1. When this product is used in combination with isoniazid or rifampicin, it may affect the blood concentration of this product. 2. When this product is used in combination with sulfonylurea hypoglycemic drugs such as tolbutamide, chlorbutamide and glipizide, the blood concentration of these drugs may increase, which may lead to hypoglycemia. Therefore, blood sugar needs to be monitored and the dose of sulfonylurea hypoglycemic drugs needs to be reduced. 3. When high doses of this product are used in combination with cyclosporine, the blood concentration of cyclosporine may increase, which may increase the risk of toxic reactions. Therefore, it must be used with caution while monitoring the blood concentration of cyclosporine and adjusting the dose. 4. When this product is used in combination with hydrochlorothiazide, the blood concentration of this product may increase. 5. When this product is used in combination with theophylline, the blood concentration of theophylline may increase by about 13%, which may lead to toxic reactions. Therefore, the blood concentration of theophylline needs to be monitored. 6. When this product is used in combination with dicoumarol anticoagulants such as warfarin, it can enhance the anticoagulant effect of dicoumarol anticoagulants and prolong the prothrombin time. Therefore, the prothrombin time should be monitored and used with caution. 7. When this product is used in combination with phenytoin sodium, the blood concentration of phenytoin sodium can be increased. Therefore, the blood concentration of phenytoin sodium needs to be monitored. 8. When this product is used in combination with short-acting benzodiazepines such as midazolam, it can cause a significant increase in the blood concentration of midazolam and psychomotor effects may occur. This effect is more obvious when taken orally than when injected intravenously. If the patient needs to receive fluconazole and benzodiazepines at the same time, the dosage of benzodiazepines should be reduced and the patient should be properly observed. 9. This product may cause adverse cardiac reactions when used in combination with cisapride, including torso diverticula.

Keep away from light and store in a sealed container.

100ml:0.2g